Serum levels of metalloproteinases-2 and -9 (MMP-2, MMP-9) - Correlation with their expression in skin lesions in systemic sclerosis - The preliminary examination;Stezenie metaloproteinazy 2 i 9 (MMP-2 i MMP-9) w surowicy chroych na twardzine układowa -Porównanie z ich ekspresja w chorobowo zmienionej skórze - Badania wstepne

Postepy Dermatologii i Alergologii

Volumn 24, Issue 2, 2007, Pages 73-81

  Dziankowska Bartkowiak, Bozena ^a   Zebrowska, Agnieszka ^a   Joss Wichman, Ewa ^a   Kobos, Józef ^a   Waszczykowska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Gelatinases A and B; Pathogenesis; Systemic sclerosis

Indexed keywords

GELATINASE A; GELATINASE B; MONOCLONAL ANTIBODY; PEROXIDASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN DEFECT; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

EID: 34249823993     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Varga J, Bashey RI. Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 1995; 12: 187-99.
2. Bogaczewicz J, Chodorowska G, Krasowska D. Rola metaloproteinaz macierzy i tkankowych inhibitorów metaloproteinaz w progresji nowotworów skóry a nowe strategie farmakologicznej inhibicji metaloproteinaz macierzy. Przeg Dermatol 2004; 91: 153-60.
3. Graesslin O, Cortez A, Uzan C, et al. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer 2006; 16: 1911-17.
4. Pesta M, Holubec L Jr, Topolcan O, et al. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 2005; 25: 3387-91.
5. Gu ZD, Li JY, Li M, et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 2005; 100: 1835-43.
6. Bjornland K, Flatmark K, Pettersen S, et al. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 2005; 127: 151-6.
7. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 2005; 30: 541-5.
8. Rannou F, Francois M, Corvol MT, Berenbaum F. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 2005; 73: 29-36.
9. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol 2005; 153: 295-300.
10. Yazawa N, Kikuchi K, Ihn H, et al. Serum levels of tissue inhibitor of metalloproteinase 2 in patients with systemic sclerosis. J Am Acad Dermatol 2000, 42: 70-5.
11. Saarialho-Kere U, Kerkela E, Jahokola T, et al. Epsilin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol 2002; 119: 14-21.
12. Krampert M, Bloch W, Sasaki T, Werner S. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell 2004; 15: 5242-54.
13. Carmichael DF, Stricklin GP, Stuart JM. Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. Agents Actions 1989; 27: 378-9.
14. Lee MM, Yoon BJ, Osiewicz K, et al. Tissue inhibitor of metalloproteinase 1 regulates resistance to infection. Infect Immun 2005; 73: 661-5.
15. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
16. Kahaleh MB, Sultany GL, Smith EA, et al. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986; 4: 367-69.
17. Ouchterlony O. Diffusion-in-gel methods for immunological analysis. In: Progress in Allergy. Callos P, Waxman BH (eds.). Karger, New York 1962; V: 30.
18. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-76.
19. Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122: 264-71.
20. Van den Steen PE, Van Aelst I, Starckx S, et al. Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria. Lab Invest 2006; 86: 873-88.
21. Krizanac-Bengez L, Hossain M, Fazio V, et al. Loss of flow induces leukocyte-mediated MMP/TIMP imbalance in dynamic in vitro blood-brain barrier model: role of pro-inflammatory cytokines. Am J Physiol Cell Physiol 2006; 291: C740-9.
22. Annala A, Koivukangas V, Salmela F, et al. Collagen synthesis markers and matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9) in the suction blister fluid and serum of juvenile diabetic patients. Eur J Dermatol 1995; 5/3: 247-52.
23. Chung AW, Hsiang YN, Matzke LA, et al. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006; 99: 140-8.
24. Kostamo K, Sorsa T, Leino M, et al. In vivo relationship between collagenase-2 and interleukin-8 but not tumour necrosis factor-alpha in chronic rhinosinusitis with nasal polyposis. Allergy 2005; 60: 1275-9.
25. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis - cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hosp Jt Dis 2006; 64: 20-4.
26. Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 2006; 33: 1523-9.
27. Toubi E, Kessel A, Grushko G, et al. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002; 20: 221-4.
28. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol 2005; 153: 295-300.
29. Laudanski P, Szamatowicz J, Ramel P. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis. Gynecol Endocrinol 2005; 21: 106-10.
30. Takeda K, Hatamochi A, Ueki H, et al. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994; 103: 359-63.
31. Kikuchi K, Kadono T, Furue M, et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108: 281-94.
32. Mattila L, Airola K, Ahonen M, et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416-21.
33. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997; 6: 199-213.
34. Bullen EC, Longaker MT, Updike DL, et al. Tissue inhibitor of matalloproteinase-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 1995; 104: 236-40.
35. Ingman T, Tervahartiala T, Ding Y, et al. Matrix metalloproteinases and their inhibitors in gingival cervicutar fluid and saliva of periodontitis patients. J Clin Periodontol 1996; 23: 1127-32.
36. Vu TH, Shipley JM, Bergers C, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411-22.
37. Fornoni A, Wang Y, Lenz O, et al. Association of a decreased number of d (CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. J Am Soc Nephrol 2002; 13: 2068-76; erratum in: J Am Soc Nephrol 2002; 13: 2617.
38. Dubois B, Masure S, Hurtenbach V, et al. Resistance of young gelatinase-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999; 104: 1507-15.
39. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105: 1641-9.
40. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
41. Kikuchi K, Kubo M, Hoashi T, et al. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol 2002; 27: 301-5.
42. Bogaczewicz J, Krasowska D, Stryjecka-Zimmer M, Chodorowska G. High serum total concentration of matrix metalloproteinase-9 (pro-MMP-9 i MMP-9) in patients with systemic sclerosis. Przegl Dermatol 2005; 3: 217-23.
43. Kobayashi T, Hattori S, Shinkai H. Matrix metalloproteinases -2 and -9 are secreted from human fibroblasts. Acta Derm Venereol 2003; 83: 105-7.
44. Giannelli G, Iannone F, Marinosci F, et al. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005; 21: 327-32.
45. Leppert D, Waubant E, Galardy R, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154: 4379-89.
46. Burger D, Rezzonico R, Li JM, et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum 1998; 41: 1748-59.
47. Zhang JH, Ferrante A, Arrigo AP, et al. Neutrophil stimulation and priming by direct contact with activated human T lymphocytes. J Immunol 1992; 148: 177-81.
48. Lacraz S, Isler P, Vey E, et al. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994; 269: 22027-33.
49. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decortin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289: 567-72.
50. Sato S, Hayakawa I, Hasegawa M, et al. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 4: 542-7.
51. Nishijima C, Hayakawa I, Matsushita T, et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004; 138: 357-63.